{"schema_version":"secwatch.filing_event.v1","accession":"0001564590-22-019075","form_type":"8-K","ticker":"COGT","cik":"0001622229","company_name":"Cogent Biosciences, Inc.","filed_at":"2022-05-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:01.521587+00:00","generated_at":"2026-06-25T21:43:22.514698+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Cogent Biosciences Q1 net loss $30.6M; cash $191M funds into 2024","bullets":["Net loss $30.6M in Q1 2022 vs. $11.7M in Q1 2021; R&D spend $25.5M (up from $8.2M).","Cash & equivalents $191.0M as of March 31, 2022, compared to $219.7M at year-end 2021.","Initial APEX Phase 2 data for bezuclastinib in AdvSM to be presented at EHA June 2022.","FGFR2 inhibitor advancing toward IND in H2 2023; ErbB2 mutant selective program announced.","SUMMIT (NonAdvSM) and PEAK (GIST) trials actively enrolling patients."],"urls":{"canonical":"https://secwatch.observer/filing/0001564590-22-019075","json":"https://secwatch.observer/filing/0001564590-22-019075.json","markdown":"https://secwatch.observer/filing/0001564590-22-019075.md","text":"https://secwatch.observer/filing/0001564590-22-019075.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1622229/000156459022019075/0001564590-22-019075-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1622229/000156459022019075/cogt-8k_20220510.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-25T21:43:22.514698+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}